New In-Demand Market Report on Lung Cancer Vaccines and Therapeutic Antibodies Now Available at MarketPublishers.com

06 Oct 2011 • by Natalie Aster
New In-Demand Market Report on Lung Cancer Vaccines and Therapeutic Antibodies Now Available at MarketPublishers.com

LONDON – Lung cancer is overall reported as being the most common cancer type. Five-year survival rates were estimated to be comparatively low (15-20%). In the US, studies have shown that lung cancer-care costs registered in 2006 were the third highest of all cancer types, and indirect costs of 2005 were far to catch up. The high instances rate of lung cancer and growing patient needs are driving the development of new therapies. Today, advances are being underway in drug treatments for lung cancer – in chemotherapy, new drug combinations and targeted molecules.

New market research reportLung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinicalworked out by Biopharm Reports has been recently published by Market Publishers Ltd.

Report Details:

Title: Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical
Published: October, 2011
Pages: 186
Price: US$ 2,384

The research features a full-view detailed review of lung cancer immunotherapy. Therapeutic vaccines and antibodies is the highlight topic of the study that also covers R&D and clinical developments in the treatment of lung cancer as the primary indication. It provides information on the studies that are evaluating lung cancer alongside other cancers and examines pipeline developments, therapeutic strategies and clinical findings, covering therapeutic vaccines and antibodies.

Reports Contents:

EXECUTIVE SUMMARY

CHAPTER 1 BACKGROUND (P.28)
Summary
1 Lung Cancer
1.1 Statistics
1.2 Diagnosis
1.3 Lung Cancer Staging
1.4 Treatment of Lung Cancer
1.5 Survival Rates
1.6 Cost of Lung Cancer
1.7 New Developments
1.8 This Report

CHAPTER 2 APPROVED AND LATE-STAGE THERAPEUTIC ANTIBODIES (P.39)
Summary
2.1 Introduction
2.2 Overview
2.3 (One antibody, Approved)
2.4 – 2.6 (Three antibodies, Phase 3)
References


CHAPTER 3 APPROVED AND LATE-STAGE VACCINES (P.52)
Summary
3.1 Introduction
3.2 Overview
3.3 (One vaccine, Approved)
3.4 – 3.6 (Three vaccines, Phase 3)
3.7 (One vaccine, Phase 2/3)
References


CHAPTER 4 EARLY-STAGE THERAPEUTIC ANTIBODIES (P.63)
Summary
4.1 Introduction
4.2 Overview
4.3 – 4.12 (Ten antibodies, Phase 2)
4.13 – 4.18 (Six antibodies, Phase 1/2)
4.19 – 4.23 (Five antibodies, Phase 1)
4.24 – 4.25 (Two Antibodies, Preclinical)
References


CHAPTER 5 EARLY-STAGE VACCINES (P.101)
Summary
5.1 Introduction
5.2 Overview
5.3 – 5.12 (Ten vaccines, Phase 2)
5.13 – 5.22 (Ten vaccines, Phase 1/2)
5.23 – 5.37 (Fifteen vaccines, Phase 1)
5.38 – 5.39 (Two vaccines, Preclinical)
References


CHAPTER 6 OTHER CANDIDATE THERAPIES (P.149)
Summary
6.1 Introduction
6.2 Overview
6.3 (One Immune Activator, Phase 2)
6.4 (One Antibody Conjugate, Phase 1/2)
6.5 (One Bispecific Antibody, Phase 1)
6.6 (One Antibody Conjugate, Phase 1)
6.7 (One Immune Stimulant, Phase 1)
6.8 (One Antibody Conjugate, Phase 1)
References

CHAPTER 7 DISCUSSION (P.160)
7.1 Background
7.2 Pipeline
7.3 Therapeutic Antibodies
7.4 Vaccines
7.5 Other Candidate Therapies
7.6 Companies
7.7 Therapeutic Targets
7.8 Therapeutic Approaches
7.9 Conditions
7.10 Market Perspectives
References


TABLES

FIGURES

More new market research reports by the publisher can be found at Biopharm Reports page.

 

CONTACTS

The Market Publishers, Ltd.

Mrs. Tanya Rezler

Tel: +44 208 123 2220

Fax: +44 207 900 3970

ps@marketpublishers.com

www.MarketPublishers.com